News

WHO includes adalimumab and ustekinumab for psoriasis, plus sunscreen for albinism, enhancing global skin health and access to essential treatments.

Quality of life improvements paralleled clinical efficacy in the CUPID studies of dupilumab.

Trial data show up to 30% of patients achieved complete response and 70% demonstrated some benefit from treatment.

Lisa Espinoza, MD, highlights the importance of patient education and tailored HA filler treatments for achieving natural cosmetic results.

Disc Medicine filed an NDA for bitopertin to treat erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) in patients ≥12 years.

Jorge Garcia-Zuazaga, MD, MBA, FAAD, FACMS, shares how Apex Skin is improving trial adherence through bilingual staff, modernizing operations with digital tools, and strengthening community partnerships.

The vaccine is designed to stimulate T cell responses against IDO1- and PD-L1–positive cells within the tumor microenvironment.

Heather Gates, PA-C, brings her dermatology expertise into a conference management business to enhance education for professionals of all levels.

ORKA-001 builds on the proven success of existing IL-23 inhibitors used in psoriasis treatment.

Lisa Espinoza, MD, discusses key insights from Allergan's Hyaluronic Acid Injectable Fillers Report, highlighting patient satisfaction and evolving aesthetic trends.

Patient advocate Danielle Jonas shares her journey with atopic dermatitis, emphasizing the importance of trusted products and clinician support during Eczema Awareness Month.

World Urticaria Day raises awareness about chronic spontaneous and inducible urticaria, highlighting treatment advancements and patient challenges.

Dermatology Times has compiled a list of dermatological meetings taking place during the month of October.

While VELA-1 achieved statistical significance under all analyses, VELA-2 narrowly missed its composite primary endpoint due to higher-than-expected placebo outcomes.

Explore insights from Renata Block DMSc, MMS, PA-C, and James Del Rosso, DO, on interpreting clinical trial data in dermatology for enhanced patient care and outcomes.

Fewer than 20% of eligible patients currently receive injectable therapies, highlighting the need for oral alternatives.

Dermatology Times is looking back on the top stories in dermatology from the month of September.

Test your knowledge of key words and terms associated with dermatology news from the last month.

Both treatments were well tolerated, with only mild, self-limiting adverse effects reported.

Dermatology Times is recapping our exclusive expert interviews from the month of September.

Many HS patients still require more aggressive or advanced treatments due to incomplete response to current options.

Mary W. Chang, MD, discusses the expanded FDA approval of ruxolitinib cream for children with atopic dermatitis and its role in addressing treatment gaps, safety, and real-world use.

Miiskin integrates generative AI into dermatology, enhancing efficiency and patient access while reducing clinician workload and administrative tasks.

Learn more about the in-depth topics covered in the September 2025 print issue of Dermatology Times.

Explore the top headlines of the month, including insights on regulatory updates, expert pearls, and more.

Phase 3 PROTOSTAR data support new indications, expanding treatment options for children impacted by chronic immune-mediated diseases.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news about upadacitinib's phase 3 efficacy in alopecia, APG777 as a potential breakthrough in AD, the latest conference insights, and more.